Vol 29, No 3 (2024)
Research paper
Published online: 2024-06-19

open access

Page views 143
Article views/downloads 0
Get Citation

Connect on Social Media

Connect on Social Media

Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines

Ovidio Hernando-Requejo1, Maria Victoria Torres Olombrada2, Irene Alda Bravo3, Leire Arbea Moreno4, Fernando Lopez Campos5, Mercedes Lopez Gonzalez1, Margarita Martín Martín5, Virginia Morillo Mascias6, Carolina de la Pinta5
DOI: 10.5603/rpor.101096
Rep Pract Oncol Radiother 2024;29(3):340-347.

Abstract

Background: The GI Tumors Workgroup, a division of the Spanish Society of Radiation Therapy, conducted a survey in December 2020 to assess the adherence of radiation oncologists in Spain to international guidelines for gastrointestinal tumors.

Materials and methods: Using Google Forms, we designed a survey covering treatments for esophageal, gastric, pancreatic, and rectal cancers.

Results: In esophageal cancer treatment, neoadjuvant chemoradiation was the standard in 76.7% of institutions. Radiation doses range from 41.1 to 50.4 Gy in conventional fractionation. Planning positron emission tomography-computed tomography (PET-CT) was performed in 83.3% of centers, and intensity-modulated radiation therapy/volumetric-arc radiation therapy (IMRT/VMAT) was the preferred technique in 86.7% of institutions.

For gastric cancer, 71.4% followed perioperative chemotherapy guidelines. In the case of adjuvant radiotherapy, the majority prescribed 45–50.4 Gy, and 82.1% used IMRT/VMAT for treatment.

For pancreas cancer, neoadjuvant chemotherapy followed by surgery in borderline resectable tumors and induction chemotherapy followed by radical radiotherapy for non-resectable tumors were the most frequent approaches. IMRT/VMAT was the primary technique.

Locally advanced rectal cancer treatment is mainly based on neoadjuvant radiotherapy in all institutions. The preferred radiation doses typically range from 45 to 50 Gy in conventional fractionation. IMRT/VMAT was standard in most Institutions.

Conclusions: Spain’s radiotherapy practices among respondents generally align with international guidelines for GI tumors highlighting Spain´s commitment to evidence-based medical practice.

Article available in PDF format

View PDF Download PDF file

References

  1. Cellini F, Manfrida S, Casà C, et al. Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. Cancers. 2022; 14(2): 431.
  2. NCCN Guidelines Version 2.2022. Esophageal and Esophagogastric Junction Cancers Continue NCCN. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433.
  3. Shah M, Kennedy E, Catenacci D, et al. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38(23): 2677–2694.
  4. Gong H, Li B. Guidelines for Radiotherapy of Esophageal Carcinoma (2020 Edition). Prec Radiat Oncol. 2021; 5(2): 54–72.
  5. Yang H, Liu H, Chen Y, et al. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma. JAMA Surg. 2021; 156(8): 721.
  6. Tepper J, Krasna M, Niedzwiecki D, et al. Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. J Clin Oncol. 2008; 26(7): 1086–1092.
  7. Shapiro J, Lanschot Jv, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9): 1090–1098.
  8. MacManus M, Nestle U, Rosenzweig K, et al. Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007. Radiother Oncol. 2009; 91(1): 85–94.
  9. Kole T, Aghayere O, Kwah J, et al. Comparison of Heart and Coronary Artery Doses Associated With Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2012; 83(5): 1580–1586.
  10. Wu V, Sham J, Kwong D. Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer. Br J Radiol. 2004; 77(919): 568–572.
  11. Wang D, Yang Y, Zhu J, et al. 3D-Conformal RT, Fixed-Field IMRT and RapidArc, Which One is Better for Esophageal Carcinoma Treated with Elective Nodal Irradiation. Technol Cancer Res Treat. 2011; 10(5): 487–494.
  12. Xu D, Li G, Li H, et al. Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer. Medicine. 2017; 96(31): e7685.
  13. Xiong BH, Cheng Y, Ma Li, et al. An Updated Meta-Analysis of Randomized Controlled Trial Assessing the Effect of Neoadjuvant Chemotherapy in Advanced Gastric Cancer. Cancer Invest. 2014; 32(6): 272–284.
  14. Slagter A, Jansen E, Laarhoven Hv, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018; 18(1).
  15. Deng HY, Wang WP, Wang YC, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. Eur J CardioThorac Surg. 2016: ezw315.
  16. Dai Q, Jiang L, Lin R, et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: A meta‐analysis of randomized controlled trials. J Surg Oncol. 2014; 111(3): 277–284.
  17. National Comprehensive Cancer Network. Gastric Cancer (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf..
  18. Bulens P, Thomas M, Deroose C, et al. PET imaging in adaptive radiotherapy of gastrointestinal tumors. Q J Nucl Med Mol Imaging. 2018; 62(4).
  19. Lambrecht M, Haustermans K. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol. 2010; 96(3): 339–346.
  20. Dębiec K, Wydmański J, Gorczewska I, et al. 18-fluorodeoxy-glucose positron emission tomography- computed tomography (18-FDG-PET/CT) for gross tumor volume (GTV) delineation in gastric cancer radiotherapy. Asian Pac J Cancer Prev. 2017; 18(11): 2989–2998.
  21. Ren F, Li S, Zhang Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiat Oncol. 2019; 14(1): 84.
  22. Perkins CL, Fox T, Elder E, et al. Image-guided radiation therapy (IGRT) in gastrointestinal tumors. J Pancreas. 2006; 7(4): 372–381.
  23. Meslar E. Pancreatic adenocarcinoma. JAAPA. 2020; 33(11): 50–51.
  24. Ducreux M, Cuhna A, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26: v56–v68.
  25. Heinrich S, Lang H. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Int J Mol Sci. 2017; 18(8): 1622.
  26. Palta M, Godfrey D, Goodman K, et al. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2019; 9(5): 322–332.
  27. Neoptolemos JP, Kerr DJ, Beger H, et al. ESPAC-1 Trial Progress Report: The European Randomized Adjuvant Study Comparing Radiochemotherapy, 6 Months Chemotherapy and Combination Therapy versus Observation in Pancreatic Cancer. Digestion. 2009; 58(6): 570–577.
  28. Hammel P, Huguet F, Laethem JLv, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA. 2016; 315(17): 1844–1855.
  29. Cellini F, Arcelli A, Simoni N, et al. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers. 2020; 12(7): 1729.
  30. Wo J, Anker CJ, Ashman JB, et al. Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Clin Pract Guid. 2021; 20(1): 438–465.
  31. Wo J, Anker C, Ashman J, et al. Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2021; 11(1): 13–25.
  32. Benson A, Venook A, Al-Hawary M, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(10): 1139–1167.
  33. Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2017; 28(Suppl 4): 22–40.
  34. Cedermark B, Glimelius B. Swedish Rectal Cancer Trial. Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. N Engl J Med. 1997; 336(14): 980–987.
  35. Sauer R, Liersch T, Merkel S, et al. Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. J Clin Oncol. 2012; 30(16): 1926–1933.